COVID-19 alters thinking and management in metabolic diseases
- PMID: 33239662
- PMCID: PMC7687210
- DOI: 10.1038/s41574-020-00449-y
COVID-19 alters thinking and management in metabolic diseases
Abstract
Metabolic diseases emerged as important risk factors for severe COVID-19, but the mechanisms responsible remained unclear for some time. The severity of metabolic diseases was also associated with worse outcomes in patients with COVID-19, forcing clinicians to adjust their thinking on which patients with metabolic disease, but without COVID-19, to prioritize for treatment during and immediately after the pandemic.
Conflict of interest statement
C.W.l.R. serves on advisory boards for Boehringer Ingelheim, GI Dynamics, Herbalife, Johnson&Johnson, Keyron, Novo Nordisk and Sanofi.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
